Th51 - High Compliance of Oral Immunotherapy and Improvement of Health-related Quality of Life in a Long-term Follow-up for Food Allergy Study

Thursday, June 23, 2022

6:15 PM – 7:30 PM PT

Presenting Author(s)

SC

Shu Cao, n/a

Biostatistician
Stanford University
Mountain View, California, United States

Co-Author(s)

LS

Liv Sullivan, n/a

Stanford University
Stanford, California, United States
KM

Kristine Martinez, n/a

Stanford University
Mountain View, California, United States
WC

William Collins, n/a

Stanford University
Mountain View, California, United States
KF

Katharaine Fast, n/a

Stanford University
Mountain View, California, United States
PG

Pooja Gajare, n/a

Stanford University
Mountain View, California, United States
Lk

Laurie kost, n/a

Stanford University
Mountain View, California, United States
SC

Sharon Chinthrajah, n/a

Stanford University
Mountain View, California, United States
SS

Sayantani Sindher, n/a

Stanford University
Mountain View, California, United States

Oral immunotherapy (OIT) has been investigated extensively in clinical studies as a promising allergen-specific approach in managing food allergies. Data on long term compliance with dose maintenance regimens is necessary to understand the durability of OIT.
Participants and caregivers who participated in OIT studies at our clinical translational research unit were contacted to respond to IRB-approved surveys: food allergy long-term follow up questionnaire (FALTFU), food allergy quality of life questionnaires (FAQOL), and burden of treatment (BOT). BOT was measured with a 1 (extremely positive) to 7 (extremely negative) scale to assess OIT treatment.
Among 148 participants responded to the FALTFU questionnaire, 108 (73%) were 12 years or young at enrollment, 70% participants incorporated at least one of their OIT foods in their daily diet. More younger participants (0-12 years) continued the food compared to older participants ( >12 years) (80% vs 40%, p< 0.001). Reasons to discontinue the food included frequent adverse reactions (n=16) and Epinephrine auto-injector (n=2). The most common OIT foods were peanut (n=124), cashew (n=38) and walnut (n=36) with 68%, 82%, and 75% participants still ingesting these foods, respectively. FAQOL improved post-study among 36 children (p< 0.001) and 39 caregivers (p< 0.001). More younger participants (0-12 years) rated slightly to extremely positive on BOT compared to older participants (87% vs 73%, p=0.048).
This is the largest OIT follow-up study showing continued dosing with food, positive perceptions of treatment with significant improvement in FAQOL. These findings were most prominent in those who started OIT at a younger age.